Brief: Botanix Pharmaceuticals Got Confirmation Sofpironium Bromide NDA Is Formally Under Review
08/12/2022 01:25
Dec 8 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* RECEIPT OF CONFIRMATION SOFPIRONIUM BROMIDE NDA IS
FORMALLY
UNDER REVIEW
Source text for Eikon: ID:nASX5QPr2n
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million